Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
SLC9A3R1 encodes a sodium/hydrogen exchanger regulatory cofactor. Additionally we are shipping Solute Carrier Family 9, Subfamily A (NHE3, Cation Proton Antiporter 3), Member 3 Regulator 1 Proteins (9) and many more products for this protein.
Showing 10 out of 108 products:
Human Monoclonal SLC9A3R1 Primary Antibody for IF, WB - ABIN968397
Bretscher, Reczek, Berryman: Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. in Journal of cell science 1998
Show all 5 references for ABIN968397
Dog (Canine) Polyclonal SLC9A3R1 Primary Antibody for IF, IHC - ABIN152695
Huang, You, Spoor, Richer, Kudva, Paige, Seiler, Liebler, Zabner, Plopper, Brody: Foxj1 is required for apical localization of ezrin in airway epithelial cells. in Journal of cell science 2003
Show all 2 references for ABIN152695
Human Polyclonal SLC9A3R1 Primary Antibody for ELISA, WB - ABIN261938
Heng, Cervero, Simon, Stephens, Li, Zhang, Paule, Rainczuk, Singh, Quinonero, Tapia, Velasquez, Salamonsen, Rombauts, Nie: Proprotein convertase 5/6 is critical for embryo implantation in women: regulating receptivity by cleaving EBP50, modulating ezrin binding, and membrane-cytoskeletal interactions. in Endocrinology 2011
Human Monoclonal SLC9A3R1 Primary Antibody for IHC (p), IP - ABIN120629
Brdicková, Brdicka, Andera, Spicka, Angelisová, Milgram, Horejsí: Interaction between two adapter proteins, PAG and EBP50: a possible link between membrane rafts and actin cytoskeleton. in FEBS letters 2001
These results indicate that PTH (show PTH Antibodies)-mediated inhibition of renal phosphate transport involves phosphorylation of S77 of the NHERF-1 PDZ (show INADL Antibodies) I domain and the dissociation of NHERF-1/Npt2a (show SLC34A1 Antibodies) complexes.
Results strongly support an important role for NHERF1 (show SLC9A3R2 Antibodies) in the regulation of Planar Cell Polarity signaling and the development of functional motile cilia.
the activation of PTEN (show PTEN Antibodies) and NHERF-1 may impede the evolution of macrophages beyond the M1 into M2 phenotype in tumor microenvironment.
Data show that interaction of the inducible nitric oxide synthase (iNOS (show NOS2 Antibodies)) C-terminus with the PDZ (show INADL Antibodies) domains of EBP50 protein or Pdzk1 (show PDZK1 Antibodies) protein CAP70 (show PDZK1 Antibodies) resulted greater nitric oxide (NO) synthesis.
The expression of EBP50 was not significantly different in the pseudopregnant uterus and decreased in the uteri subjected to activation of delayed implantation.
NHERF1 (show SLC9A3R2 Antibodies) is differentially distributed to rafts and non-raft brush border membrane fractions of NHE3 (show SLC9A3 Antibodies).
EBP50 expression is induced by inflammatory stimuli and potentiates NF-kappaB (show NFKB1 Antibodies) activation and inflammation in primary macrophages and VSMC.
siRNA knockdown of PEX7 (show PEX7 Antibodies) reduced iNOS (show NOS2 Antibodies) colocalization with the peroxisomal protein (show FNDC5 Antibodies) PMP70 (show ABCD3 Antibodies). Proteomic studies using MALDI-MS identified iNOS (show NOS2 Antibodies) association with the 50-kD ezrin (show EZR Antibodies) binding PDZ protein (show INADL Antibodies) (EBP50).
EBP50 promotes focal adhesion turnover and vascular smooth muscle cells migration.
NHERF1 (show SLC9A3R2 Antibodies) regulates PTH (show PTH Antibodies) that differentially affects Na-dependent Pi transport at distinct stages of osteoblast proliferation and maturation
study found mainly nuclear localization of EBP50 in interphase cells, and its redistribution to cytoplasm during mitosis parallel with its phosphorylation; PP2A (show PPP2R2B Antibodies) was identified as an interacting protein of EBP50 during pro-, prometa-, meta-, ana (show BTG3 Antibodies)-, telophase, and early cytokinesis
Wild-type NHERF1 acts as a tumour suppressor, while NHERF1 A190D mutation abolishes the tumour-suppressive effect in cancer cells, due to A190D mutation-mediated nuclear NHERF1 translocation and induction of YAP (show YAP1 Antibodies) phosphorylation.
the distribution of NHERF1 in ovarian cancer and reveals a different regulation of NHERF1 and EZRIN (show EZR Antibodies) expression in ovarian tumors which represents the complexity of the molecular changes of this disease
This study sheds light on a possible therapeutic strategy targeting at the aberrant nuclear expression of EBP50 without affecting the normal physiological function of EBP50 at other subcellular localization.
A novel NHERF1 mutation in human breast cancer cells inactivates inhibition of EGFR (show EGFR Antibodies) signaling by NHERF1 promoting disease progression.
The decrease in BECN1 degradation induced by SLC9A3R1 resulted in the activity of autophagy stimulation in breast cancer cells
Results showed that EBP50 specifically scaffolds the interaction of PTEN (show PTEN Antibodies) with EGFR (show EGFR Antibodies) and enhances the inhibition of PTEN (show PTEN Antibodies) on EGF (show EGF Antibodies)-induced AKT (show AKT1 Antibodies) activation. These results elucidated a novel mechanism regulating EGF (show EGF Antibodies)-induced AKT (show AKT1 Antibodies) signaling.
autosomal-dominant polycystic kidney disease is associated with a decrease in NHERF1 protein and mRNA levels.
Interaction of ABCB4 (show ABCB4 Antibodies) with EBP50 through its PDZ (show INADL Antibodies)-like motif plays a critical role in the regulation of ABCB4 (show ABCB4 Antibodies) expression and stability at the canalicular plasma membrane.
This study identified alpha-actinin-4 (show ACTN4 Antibodies) as a novel NHERF1 interaction partner and provided new insights into the regulatory mechanism of the actin cytoskeleton by NHERF1.
deuterium uptake profiles of isolated PDZ1 and PDZ2 were similar to those of full-length EBP50. Interestingly, PDZ1 was more dynamic than PDZ2, and these PDZ (show INADL Antibodies) domains underwent different conformational changes upon ligand binding
This gene encodes a sodium/hydrogen exchanger regulatory cofactor. The protein interacts with and regulates various proteins including the cystic fibrosis transmembrane conductance regulator and G-protein coupled receptors such as the beta2-adrenergic receptor and the parathyroid hormone 1 receptor. The protein also interacts with proteins that function as linkers between integral membrane and cytoskeletal proteins. The protein localizes to actin-rich structures including membrane ruffles, microvilli, and filopodia. Mutations in this gene result in hypophosphatemic nephrolithiasis/osteoporosis type 2, and loss of heterozygosity of this gene is implicated in breast cancer.
, Na(+)/H(+) exchange regulatory cofactor NHE-RF1
, ezrin-radixin-moesin-binding phosphoprotein 50
, regulatory cofactor of Na(+)/H(+) exchanger
, sodium-hydrogen exchanger regulatory factor 1
, solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 1
, solute carrier family 9 isoform A3 regulatory factor 1
, Na(+)/H(+) exchange regulatory cofactor NHE-RF
, ezrin-radixin-moesin binding phosphoprotein-50
, solute carrier family 9 isoform 3 regulatory factor 1
, Na+/H+ exchange regulatory co-factor
, solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulatory factor 1
, solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1
, ERM-binding phosphoprotein